Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 4/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404162 | 0.90 | GABRA1 (0.81) | GABRA1GABRB2MGLLCYP2D6PDK2 | |
| SCHEMBL16953362 | 0.88 | GABRA1 (0.77) | GABRA1GABRB2DAO | |
| SCHEMBL2403346 | 0.87 | GABRA1 (0.76) | GABRA1GABRB2MGLLCYP2D6PDK2 | |
| SCHEMBL3158096 | 0.85 | GABRA1 (0.73) | GABRA1GABRB2TAAR1TP53 | |
| SCHEMBL11414765 | 0.83 | GABRA1 (0.70) | GABRA1GABRB2MGLLCYP2D6PDK2 | |
| SCHEMBL6842382 | 0.83 | GABRA1 (0.70) | GABRA1GABRB2MAPTTSHR | |
| SCHEMBL16952291 | 0.83 | GABRA1 (0.70) | GABRA1GABRB2MGLLCYP2D6PDK2 | |
| SCHEMBL16941868 | 0.83 | GABRA1 (0.70) | GABRA1GABRB2TAAR1 | |
| SCHEMBL2498507 | 0.83 | GABRA1 (0.70) | GABRA1GABRB2DAO | |
| SCHEMBL8159492 | 0.83 | GABRA1 (0.70) | GABRA1GABRB2MGLLCYP2D6PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1409699-A | Process for preparation of secondary and tertiary amines | CELGRO (US) | 2003-04-09 | — | — | CN | claimed |
| EP-1237844-A1 | PROCESS FOR THE PREPARATION OF SECONDARY AND TERTIARY AMINES | Celgro (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001044162-A1 | PROCESS FOR THE PREPARATION OF SECONDARY AND TERTIARY AMINES | CELGRO (US) | 2001-06-21 | — | — | WO | claimed |
| US-6107521-A | Process for the preparation of secondary amines | CELGRO (US) | 2000-08-22 | — | — | US | claimed |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | LIFEMINE THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137071-A2 | TRIESTER COMPOUNDS AND METHODS OF USE THEREOF | LIFEMINE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-110198928-B | Benzyloxy-pyridinyl-cyclopropanecarboxylic acid, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-111518004-B | Aryl dithio formate compound with large steric hindrance group and application thereof | 中山大学 | 2021-10-26 | — | — | CN | disclosed |
| CN-109021022-B | Luminescent diazabenzimidazole carbene metal complexes | UDC 爱尔兰有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| US-10913720-B2 | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| CN-111518004-A | Aryl dithio formate compound with large steric hindrance group and application thereof | 中山大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2002059096-A1 | PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES | LUMIGEN, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1355786-A | Substituted arylmalonic acid dinitriles as intermediates for preparation of herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2002-06-26 | — | — | CN | disclosed |
| EP-1173519-A1 | NOVEL CARBOPYRONINE FLUORESCENCE DYES | DREXHAGE, Karl-Heinz (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064986-A1 | NOVEL CARBOPYRONINE FLUORESCENCE DYES | DREXHAGE KARL HEINZ (DE) | 2000-11-02 | — | — | WO | disclosed |
| US-6107521-A | Process for the preparation of secondary amines | CELGRO (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0276980-B1 | CHROMOGENIC FLUORAN COMPOUNDS | ESCO Company Limited Partnership (US) | 1992-09-23 | — | — | EP | disclosed |
| US-4879398-A | Process for producing 2,6-disubstituted tyrosine | MONSANTO COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0276980-A2 | Chromogenic fluoran compounds | ESCO Company Limited Partnership (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913720-B2 | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR52 | GABRA1 128/4885GABRB2 115/4885MGLL 1068/4885 |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | CYP46A1, CYP17A1, CYP27A1 | GABRA1 2989/4885GABRB2 2034/4885MGLL 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.